FDA Approval Sought for Margetuximab in HER2+ Metastatic Breast Cancer

A biologics license application has been submitted to the FDA for margetuximab for use in combination with chemotherapy as a treatment for patients with metastatic HER2-positive breast cancer.

Read the full article here

Related Articles